Gilead Sciences Says Lenacapavir 'Highly Effective' in HIV Prevention in Phase 3 Study
Gilead Sciences Says Lenacapavir 'Highly Effective' in HIV Prevention in Phase 3 Study
吉利德科学公司表示,在3期研究中,Lenacapavir在艾滋病预防方面非常有效。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册